iRegene Therapeutics has reached a major regulatory milestone with its lead program for Parkinson’s disease, as the U.S. Food and Drug Administration granted Regenerative Medicine Advanced Therapy (RMAT) designation to NouvNeu001. The designation underscores growing regulatory confidence in the company’s approach and positions the therapy for an accelerated development and review pathway in the United States.
NouvNeu001 is an allogeneic, induced pluripotent stem cell (iPSC)–derived cell therapy developed using iRegene’s proprietary chemical induction platform. With the latest decision, the therapy becomes the first allogeneic iPSC-derived cell therapy worldwide to hold both FDA Fast Track Designation and RMAT status. The Fast Track Designation was awarded in August 2025, and together the two recognitions highlight the FDA’s assessment of the therapy’s potential to address a serious unmet need in Parkinson’s disease.
Parkinson’s disease is a progressive neurodegenerative disorder that affects millions of people globally and is characterized by the gradual loss of dopamine-producing neurons, leading to tremors, rigidity, slowed movement, and impaired balance. Current treatments primarily manage symptoms and do not halt or reverse disease progression. iRegene’s NouvNeu001 is designed to modify the underlying disease process by replacing or restoring damaged neural function, offering the possibility of more durable clinical benefit.
The RMAT designation was established under the 21st Century Cures Act to speed the development of regenerative medicine therapies intended to treat, modify, reverse, or cure serious or life-threatening conditions. Products granted RMAT status may benefit from early and frequent interactions with the FDA, as well as eligibility for accelerated approval and priority review, depending on clinical data. These regulatory advantages are intended to reduce development timelines and facilitate faster patient access to promising therapies.
According to iRegene, the designation reflects encouraging clinical data generated to date, as well as the novelty of its chemically induced allogeneic cell therapy platform. The company plans to leverage the RMAT framework to intensify collaboration with regulators as it advances its global clinical development program.
Company leadership emphasized that the milestone strengthens iRegene’s mission to deliver transformative regenerative therapies. With both Fast Track and RMAT designations in place, iRegene is aiming to accelerate clinical progress for NouvNeu001 and move closer to offering a potentially disease-modifying treatment option for patients living with Parkinson’s disease.